Publication:
C6orf15 expression in thyroid tumors: A promising diagnostic biomarker for the classic variant of papillary thyroid carcinoma

Loading...
Thumbnail Image
Date
2026
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Pengju Zhang ; Jiaxin Chai ; Jiandong Wang ; Pengfei Huang ; Xudong Gu ; Aobo Xu
item.page.secondaryauthor
item.page.director
Publisher
publication.page.editor
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.department
DOI
https://doi.org/10.14670/HH-25-007
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Although C6orf15 is highly expressed in certain human cancers, its expression pattern in papillary tumors remains unclear. In this study, we investigated C6orf15 expression in papillary tumors and assessed its potential as a diagnostic biomarker for histopathological evaluation and fine-needle aspiration cytology (FNAC). We collected a total of 87 formalin-fixed and paraffin embedded (FFPE) thyroid tissue specimens that included: 10 cases with Hashimoto's thyroiditis (HT), 11 with follicular adenomas (FAs), two with non-invasive follicular thyroid neoplasms with papillary-like nuclear feature (NIFTP), six with follicular thyroid carcinomas (FTCs), three with invasive encapsulated follicular variant of papillary thyroid carcinomas (IEFVPTCs), three with medullary thyroid carcinomas (MTCs), and 52 with papillary thyroid carcinomas (PTCs). Additionally, 33 FNAC samples from thyroid nodules were analyzed, comprising three samples of FA, five atypia of undetermined significance (AUS), and 25 cases of PTC. Immunohistochemical (IHC) staining was performed to assess C6orf15 expression in thyroid tumor tissues and FNAC samples. We conducted BRAF V600E mutation analysis via Sanger sequencing and IHC and discerned that C6orf15 expression was absent in normal follicular epithelial cells, FA, NIFTP, TFC, and MTC. The positivity rates for C6orf15 in FFPE samples were as follows: 66.7% for IEFVPTC, 86.5% for PTC, and 60.0% for AUS. In FNAC samples, the positivity rate was 80.0% for PTC. A significant positive correlation was observed between C6orf15 expression and the BRAF V600E mutation in PTC tissues (p<0.001), but no such association was found in FNAC samples (p=0.230). C6orf15 exhibited high expression levels in the majority of IEFVPTC (66.7%), PTC tissues (86.5%), and FNAC samples (80.0%). These findings suggest that C6orf15 constitutes a promising diagnostic biomarker for the classic variant of PTC and is applicable to histo pathological assessment and FNAC-based diagnosis.
Citation
item.page.embargo